{"id":2977,"date":"2026-05-20T16:39:12","date_gmt":"2026-05-20T09:39:12","guid":{"rendered":"https:\/\/naviva.com.vn\/?p=2977"},"modified":"2026-05-21T08:04:17","modified_gmt":"2026-05-21T01:04:17","slug":"scientific-symposium-varicella-second-generation-mav-06-vaccine-and-updates-from-the-world-health-organization-who","status":"publish","type":"post","link":"https:\/\/naviva.com.vn\/en\/scientific-symposium-varicella-second-generation-mav-06-vaccine-and-updates-from-the-world-health-organization-who","title":{"rendered":"Scientific Symposium: VARICELLA – SECOND-GENERATION MAV\/06 VACCINE AND UPDATES FROM THE WORLD HEALTH ORGANIZATION (WHO)"},"content":{"rendered":"

On May 9, 2026, the Vietnam Association of Preventive Medicine, in collaboration with NAVIVA Group and GC Biopharma, organized the scientific symposium \u201cVaricella – Second-Generation MAV\/06 Vaccine and Updates from the World Health Organization (WHO).\u201d The symposium focused on updating scientific information on the epidemiology, treatment, and prevention of varicella through vaccination, along with the latest WHO recommendations aimed at enhancing disease prevention effectiveness in the community.<\/span><\/p>\n

\"\"<\/a><\/p>\n

\"\"<\/a><\/p>\n

\"\"<\/a><\/p>\n

Image: <\/span>Scientific Symposium: VARICELLA \u2013 SECOND-GENERATION MAV\/06 VACCINE AND UPDATES FROM THE WORLD HEALTH ORGANIZATION (WHO)<\/span><\/i><\/span><\/p>\n

As varicella continues to record many cases among young children and within school environments, medical experts recommend that parents should not be complacent about this disease.<\/span><\/p>\n

Dr. Do Thien Hai, Deputy Director of the Center for Tropical Diseases at the National Children\u2019s Hospital, stated that many parents still consider varicella as a mild disease and therefore remain complacent in monitoring and isolating infected children. According to medical experts, varicella not only affects daily activities and learning, but can also lead to serious complications such as pneumonia, encephalitis, and skin infections, particularly in newborns, pregnant women, and immunocompromised individuals.<\/span><\/p>\n

Assoc. Prof. Dr. Pham Quang Thai, Deputy Head of the Department of Infectious Disease Control at the National Institute of Hygiene and Epidemiology, stated that varicella causes more than 4,200 deaths globally each year. The disease is highly contagious and can even be transmitted during the incubation period before symptoms appear, with one infected individual capable of transmitting the disease to 12 to 18 others.<\/span><\/p>\n

In Vietnam, varicella consistently ranks among the five most common infectious diseases. Since 2023, the number of reported cases has shown an upward trend again, highlighting the persistent risk of outbreaks if high and uniform vaccination coverage is not maintained across the community.<\/span><\/p>\n

Currently, children under 10 years of age are considered the priority group for protection, particularly those aged 1 to 9 years, who account for the highest incidence of varicella infection. Under normal conditions, experts consider 12 months of age to be the optimal time for administration of the first vaccine dose in order to achieve an adequate immune response. Vaccination at an earlier age may result in a suboptimal immune response due to the persistence of maternally derived antibodies during the first months of life. Multiple studies have demonstrated that vaccination from 12 months of age provides significantly higher immunogenicity compared with vaccination at 9 months of age.<\/span><\/p>\n

At the symposium, Assoc. Prof. Dr. Hyun Mi Kang, Visiting Scientist at Boston Children\u2019s Hospital, Harvard University, Associate Professor at Seoul St. Mary\u2019s Hospital, and member of the International Network of Special Immunization Services (INSIS), also presented updates from the World Health Organization regarding the second-generation MAV\/06 strain varicella vaccine.<\/span><\/p>\n

This vaccine has demonstrated high immunogenicity and a well-established safety profile recognized by the World Health Organization (WHO). In the latest WHO position paper published in November 2025, updated guidance regarding the safety of interchangeability between MAV\/06 strain and Oka strain varicella vaccines was also included.<\/span><\/p>\n

A two-dose varicella vaccination schedule to achieve optimal immunity is currently recommended by international health organizations, as well as in South Korea and Vietnam, in order to enhance protective efficacy and maintain long-term immunity.<\/span><\/p>\n

Representing vaccine manufacturer GC Biopharma, Ms. Jihyun Bae, Medical Science Liaison at GC Biopharma, Doctor of Pharmacy from Rutgers University, USA, and FDA research fellow, also shared notable achievements of the MAV\/06 strain varicella vaccine from the first generation to the second generation. The vaccine has been utilized in more than 30 countries for over 30 years, with more than 30 million doses administered, alongside advancements in automated, closed-system manufacturing technology and the use of WHO-recommended cell lines.<\/span><\/p>\n

Meeting stringent quality standards, the second-generation MAV\/06 strain varicella vaccine possesses outstanding characteristics and represents a leading trend in vaccine manufacturing technology. The vaccine has also achieved WHO Prequalification (WHO PQ) certification.<\/span><\/p>\n

The second-generation MAV\/06 strain vaccine does not contain antibiotics in its formulation, providing important benefits for vaccinated children by eliminating the risk of antibiotic-related allergic reactions and offering a safer option for individuals with hypersensitivity conditions.<\/span><\/p>\n

NAVIVA Group would like to sincerely thank our valued partners, distinguished speakers, and all esteemed guests for their presence and meaningful contributions. Your insights, questions, and perspectives contributed significantly to the core value of the symposium, serving as a platform for scientific exchange and updates in the field of vaccines, with the shared goal of protecting the community against the risk of varicella.<\/span><\/p>\n

We look forward to your continued companionship with NAVIVA Group at our upcoming events. We remain committed to delivering in-depth, up-to-date, and highly valuable scientific symposiums that contribute positively to Vietnam\u2019s healthcare community, support the advancement of immunization practices, and promote the protection of public health.<\/span><\/p>\n

NAVIVA Group \u2013 Community Health is Our Happiness!<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

On May 9, 2026, the Vietnam Association of Preventive Medicine, in collaboration with NAVIVA Group and GC Biopharma, organized the scientific symposium \u201cVaricella – Second-Generation MAV\/06 Vaccine and Updates from the World Health Organization (WHO).\u201d The symposium focused on updating scientific information on the epidemiology, treatment, and prevention of varicella through vaccination, along with the […] <\/p>\n","protected":false},"author":4,"featured_media":2974,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[25],"tags":[],"class_list":["post-2977","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts\/2977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/comments?post=2977"}],"version-history":[{"count":2,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts\/2977\/revisions"}],"predecessor-version":[{"id":2979,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts\/2977\/revisions\/2979"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/media\/2974"}],"wp:attachment":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/media?parent=2977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/categories?post=2977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/tags?post=2977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}